Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

Hepatology - Tập 37 Số 2 - Trang 343-350 - 2003
Zhiping Li1, Shiqi Yang1, Huizhi Lin1, Jiawen Huang1, Paul A. Watkins2,1, Ann B. Moser2,1, Claudio Desimone3, Xiaoyu Song4, Anna Mae Diehl1
1The Johns Hopkins University, Baltimore, MD
2Kennedy Krieger Institute, Baltimore, MD
3University of L'Aquila, L'Aquila ,Italy#TAB#
4Centocor, Malvern, Pa

Tóm tắt

Ob/ob mice, a model for nonalcoholic fatty liver disease (NAFLD), develop intestinal bacterial overgrowth and overexpress tumor necrosis factor α (TNF-α). In animal models for alcoholic fatty liver disease (AFLD), decontaminating the intestine or inhibiting TNF-α improves AFLD. Because AFLD and NAFLD may have a similar pathogenesis, treatment with a probiotic (to modify the intestinal flora) or anti-TNF antibodies (to inhibit TNF-α activity) may improve NAFLD in ob/ob mice. To evaluate this hypothesis, 48 ob/ob mice were given either a high-fat diet alone (ob/ob controls) or the same diet + VSL#3 probiotic or anti-TNF antibodies for 4 weeks. Twelve lean littermates fed a high-fat diet served as controls. Treatment with VSL#3 or anti-TNF antibodies improved liver histology, reduced hepatic total fatty acid content, and decreased serum alanine aminotransferase (ALT) levels. These benefits were associated with decreased hepatic expression of TNF-α messenger RNA (mRNA) in mice treated with anti-TNF antibodies but not in mice treated with VSL#3. Nevertheless, both treatments reduced activity of Jun N-terminal kinase (JNK), a TNF-regulated kinase that promotes insulin resistance, and decreased the DNA binding activity of nuclear factor κB (NF-κB), the target of IKKβ, another TNF-regulated enzyme that causes insulin resistance. Consistent with treatment-related improvements in hepatic insulin resistance, fatty acid β-oxidation and uncoupling protein (UCP)-2 expression decreased after treatment with VSL#3 or anti-TNF antibodies. In conclusion, these results support the concept that intestinal bacteria induce endogenous signals that play a pathogenic role in hepatic insulin resistance and NAFLD and suggest novel therapies for these common conditions.

Từ khóa


Tài liệu tham khảo

Nomura, 1988, Jpn J Med, 27, 142, 10.2169/internalmedicine1962.27.142

Bellentani, 2000, Ann Intern Med, 132, 112, 10.7326/0003-4819-132-2-200001180-00004

, . Nonalcoholic fatty liver disease and its correlates in the United States. Am J Gastroenterol (in press).

Matteoni, 1999, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8

Menon, 2001, Mayo Clin Proc, 76, 1021, 10.4065/76.10.1021

Pares, 1986, J Hepatol, 2, 33, 10.1016/S0168-8278(86)80006-X

Galambos, 1972, Gastroenterology, 56, 515

Iimuro, 1997, Hepatology, 26, 1530, 10.1002/hep.510260621

Adachi, 1995, Gastroenterology, 108, 218, 10.1016/0016-5085(95)90027-6

Nanji, 1994, Proc Soc Exp Biol Med, 205, 243, 10.3181/00379727-205-43703

Imperiale, 1990, Ann Intern Med, 113, 299, 10.7326/0003-4819-113-4-299

Akriviadis, 2000, Gastroenterology, 119, 1637, 10.1053/gast.2000.20189

Yen, 1977, Experientia, 33, 995, 10.1007/BF01945927

Yen, 1976, Biochim Biophys Acta, 441, 213, 10.1016/0005-2760(76)90164-8

Austin, 1984, Exp Gerontol, 19, 121, 10.1016/0531-5565(84)90015-9

Cope, 2000, Gastroenterology, 119, 1340, 10.1053/gast.2000.19267

Lin, 2000, Nat Med, 6, 998, 10.1038/79697

Solomon, 1997, Horm Metab Res, 29, 379, 10.1055/s-2007-979059

Uysal, 1997, Nature, 389, 610, 10.1038/39335

Brigidi, 2000, Syst Appl Microbiol, 23, 391, 10.1016/S0723-2020(00)80070-3

Venturi, 1999, Aliment Pharmacol Ther, 13, 1103, 10.1046/j.1365-2036.1999.00560.x

Aguirre, 2000, J Biol Chem, 275, 9047, 10.1074/jbc.275.12.9047

Aggarwal, 2000, Ann Rheum Dis, 59, i6, 10.1136/ard.59.suppl_1.i6

Folch, 1957, J Biol Chem, 226, 457, 10.1016/S0021-9258(18)64849-5

Moser, 1999, Neurochem Res, 24, 187, 10.1023/A:1022549618333

Yang, 2001, Am J Physiol, 281, g382

Chomczynski, 1987, Anal Biochem, 162, 156, 10.1016/0003-2697(87)90021-2

Diehl, 1994, Am J Physiol, 267, g552

Yang, 1998, Am J Physiol, 275, g696, 10.1152/ajpcell.1998.275.3.C675

Watkins, 1991, Arch Biochem Biophys, 289, 329, 10.1016/0003-9861(91)90419-J

Yuan, 2001, Science, 293, 1673, 10.1126/science.1061620

Stancovski, 1997, Cell, 91, 299, 10.1016/S0092-8674(00)80413-4

Cohen, 2002, Science, 297, 240, 10.1126/science.1071527

Sanyal, 2001, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256

De Fronzo, 1991, Diabetes Care, 14, 173, 10.2337/diacare.14.3.173

Li, 2002, Endocrinology, 143, 1371, 10.1210/endo.143.4.8717

Cortez-Pinto, 1998, Biochem Biophys Res Commun, 251, 313, 10.1006/bbrc.1998.9473

Chavin, 1999, J Biol Chem, 274, 5692, 10.1074/jbc.274.9.5692

Haines, 1981, Hepatology, 1, 161, 10.1002/hep.1840010212

Wigg, 2001, Gut, 48, 206, 10.1136/gut.48.2.206

Koteish, 2001, Semin Liver Dis, 21, 89, 10.1055/s-2001-12932

Tobe, 2001, J Biol Chem, 276, 38337, 10.1074/jbc.C100160200

Kim, 2001, Proc Natl Acad Sci U S A, 98, 7522, 10.1073/pnas.121164498

Marchesini, 1999, Am J Med, 107, 450, 10.1016/S0002-9343(99)00271-5

Memon, 2001, Nat Med, 7, 2, 10.1038/83316

Yang, 1997, Proc Natl Acad Sci U S A, 94, 2557, 10.1073/pnas.94.6.2557

Marchesini, 2001, Lancet, 358, 893, 10.1016/S0140-6736(01)06042-1

Liedtke, 2002, Hepatology, 36, 315, 10.1053/jhep.2002.34615

Loguercio, 2002, Am J Gastroenterol, 97, 2144, 10.1111/j.1572-0241.2002.05942.x

Roden, 2001, Recent Prog Horm Res, 56, 219, 10.1210/rp.56.1.219

Thông tin
Thông tin xuất bản

Hepatology

Tập 37 Số 2

343-350

Thông tin tác giả